1. Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
- Author
-
Grieco A, Tafuri MA, Biolato M, Diletto B, Di Napoli N, Balducci N, Vecchio FM, and Miele L
- Subjects
- Aged, Antineoplastic Agents, Alkylating administration & dosage, Brain Neoplasms drug therapy, Chemical and Drug Induced Liver Injury diagnosis, Dacarbazine administration & dosage, Dacarbazine adverse effects, Fatal Outcome, Glioblastoma drug therapy, Humans, Male, Temozolomide, Antineoplastic Agents, Alkylating adverse effects, Chemical and Drug Induced Liver Injury etiology, Cholestasis chemically induced, Dacarbazine analogs & derivatives
- Abstract
Temozolomide is the current standard of therapy for postoperative patients with glioblastoma starting adjuvant radiotherapy. Hematologic adverse events are the most frequent side effects of temozolomide, while liver toxicity has been reported only in the post-marketing period. Here we report a case of severe temozolomide-induced liver injury during concurrent radiotherapy treatment, at a dose level of 75âmg/m2. The aim of this case report is to focus on the problems of temozolomide-induced hepatotoxicity. In conclusion, a close monitoring of liver function tests is recommended during treatment with temozolomide.
- Published
- 2015
- Full Text
- View/download PDF